Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Campbell Newman Asset Management Inc.

Campbell Newman Asset Management Inc. decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,550 shares of the medical equipment provider’s stock after selling 112 shares during the period. Campbell Newman Asset Management Inc.’s holdings in Lantheus were worth $3,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus in the third quarter valued at approximately $25,000. Signaturefd LLC raised its stake in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. Nkcfo LLC acquired a new stake in Lantheus during the 2nd quarter worth $47,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in shares of Lantheus in the third quarter valued at about $51,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 1.5 %

Shares of NASDAQ LNTH traded up $1.43 during trading on Wednesday, hitting $94.05. 18,045 shares of the company traded hands, compared to its average volume of 745,332. The firm has a market capitalization of $6.54 billion, a P/E ratio of 15.65 and a beta of 0.46. The company has a 50-day moving average price of $89.53 and a 200-day moving average price of $99.87. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89.

Analysts Set New Price Targets

Several analysts have issued reports on the company. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average price target of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.